Flinn
Category: AI in Healthcare
An AI-powered platform that automates regulatory and quality compliance processes for medical device manufacturers and pharmaceutical companies, enabling 10x more efficient product launches and operations. Flinn was founded in 2022. The company is led by Bastian Krapinger-Rüther. Based in Vienna, Austria. Team size: 40-50. Total funding raised: $28.0M. Latest round: Series A (€17M, Feb 2026). Key investors include ["HV Capital","Bertelsmann Healthcare Investments (BHI)","Cherry Ventures","Speedinvest","SquareOne Venture Capital"].
- Founded
- 2022
- Headquarters
- Vienna, Austria
- Team size
- 40-50
- Total funding
- $28.0M
Value proposition
Replaces manual, document-heavy compliance workflows with intelligent AI automation, reducing administrative workload by months while ensuring full MDR/IVDR compliance, enabling manufacturers to launch and operate products 10x more efficiently.
Products and solutions
["Post-Market Surveillance (PMS) Automation - Automated data collection, evaluation, and reporting","AI-Powered Literature Evaluation - Abstract screening, full-text access, and clinical data extraction for CERs","Regulatory Monitoring Dashboard - Real-time tracking of 40M+ publications and regulatory changes","Complaint Handling & Incident Reporting - Automated evaluation of 20M+ incident reports","Clinical Evaluation Report (CER) Writing Assistant - AI-assisted table creation, text drafting, and citations","PMCF/PMPF Automation - Post-Market Clinical/Performance Follow-Up management"]
Unique value
First-to-market AI-Copilot purpose-built exclusively for MedTech compliance that integrates agentic AI with regulatory expertise. Monitors and analyzes 40+ million life science publications, 20+ million incident reports, millions of complaints, and hundreds of global standards in real-time. Features embedded literature purchasing and seamless integration with existing QM/RA processes.
Target customer
Medical device manufacturers (Class I-III devices), pharmaceutical companies, in-vitro diagnostic manufacturers operating under MDR/IVDR regulatory frameworks
Industries served
["Medical Technology (MedTech)","Pharmaceutical Manufacturing","In-Vitro Diagnostics (IVD)","Healthcare Regulatory Compliance","Medical Device Quality Management"]
Technology advantage
Combines proprietary AI data extraction with MDR/IVDR regulatory logic to deliver audit-ready compliance documentation. Platform enables one-click report generation, multi-database search capability, and maintains full user review control while automating repetitive form-filling workflows. Achieves regulatory accuracy standards required for safety-critical, regulated environments while delivering 10x operational efficiency gains.
How they differentiate
First-to-market AI-Copilot purpose-built exclusively for MedTech compliance automation, monitoring 40M+ life science publications and 20M+ incident reports in real-time. Unlike traditional QMS platforms, Flinn focuses specifically on post-market surveillance automation with proprietary AI-driven regulatory intelligence and MDR/IVDR domain expertise.
Main competitors
["Greenlight Guru","Ketryx","Enzyme"]
Key partnerships
["qtec Services GmbH - MDR-compliant support in risk management, clinical evaluation, and regulatory affairs throughout product lifecycle","MIRA.Digital GmbH - Embedded literature purchasing and license-handling integration for scientific publications","avasis solutions GmbH - API integration connecting Flinn with Polarion PLM platform for clinical evaluations and PMS","Strategic advisors including former MedTech executives (Matthias Weber - former president Leica Biosystems, Michael Reitermann - former CEO Siemens Diagnostics)"]
Notable customers
["Carl Zeiss","Philips","Paul Hartmann"]
Major milestones
["€6M Seed round led by Cherry Ventures (Oct 2024)","€17M ($20M) Series A led by HV Capital with BHI participation (Feb 2026)","Achieved 100+ customer milestone across 14 countries","Expanded product to cover full MedTech/Pharma lifecycle from development to post-market","Strategic partnerships with qtec Services, MIRA.Digital, and avasis solutions","ISO 27001, ISO 14971, and FDA 21 CFR Part 11 compliance certifications"]
Growth metrics
Reached 100+ MedTech company customers across 14 countries within 3 years; 40-50 employees; offices in Vienna, Berlin, and Paris; ~$5.2M ARR (estimated 2025)
Market positioning
European growth-stage SaaS challenger targeting mid-market to enterprise MedTech manufacturers (Class I-III devices) and pharma companies, with proven traction serving 100+ customers across 14 countries including industry leaders like Carl Zeiss, Philips, and Paul Hartmann.
Geographic focus
Europe (Vienna, Berlin, Paris offices; 14 countries currently served), with planned US market entry in 2026 following Series A funding
Patents and IP
No registered patents disclosed publicly as of February 2026. Focus appears to be on proprietary AI algorithms and regulatory logic rather than patent protection.
About Bastian Krapinger-Rüther
Former MedTech founder and CEO (MEON Medical Solutions - Roche Diagnostics spinoff; Carbomed Medical Solutions - FemTech fertility tracking company), N26 alumnus, MSc in Strategy, Innovation and Management Control from WU Vienna
Official website: https://www.flinn.ai